{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:56Z","timestamp":1781636096599,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurofilament light chain (NfL) is a sensitive biomarker of axonal damage, but its clinical relevance in chronic autoimmune neuropathies remains incompletely defined. This study evaluated plasma NfL levels in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), compared with hereditary neuropathy (Charcot\u2013Marie\u2013Tooth disease type 1\u00a0A, CMT1A) and healthy controls, focusing on disease activity rather than diagnostic discrimination. Plasma NfL concentrations were measured using single molecule array (Simoa) technology in 41 patients (CIDP\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916, MMN\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097, CMT1A\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918) and 25 age- and sex-matched controls. Disease severity was assessed using the Inflammatory Rasch-built Overall Disability Scale for autoimmune neuropathies and the Charcot\u2013Marie\u2013Tooth Neuropathy Score version 2 for CMT. Plasma NfL levels were significantly higher in patients with autoimmune neuropathies and CMT compared with controls. No significant differences were observed between inflammatory and hereditary neuropathies, and NfL levels did not correlate with disability scores. However, patients with autoimmune neuropathies and an unstable disease course, defined by more than two relapses, exhibited significantly higher plasma NfL levels. Across all groups, NfL concentrations showed a strong correlation with age. These findings suggest that while plasma NfL lacks diagnostic specificity among chronic neuropathies, it may be associated with disease instability in autoimmune neuropathies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-39803-x","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:44:05Z","timestamp":1771220645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma neurofilament light chain is associated with clinical instability in chronic autoimmune neuropathies"],"prefix":"10.1038","volume":"16","author":[{"given":"Ieva","family":"Gl\u0101zere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Roddate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"\u017dukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u013cja","family":"Kurj\u0101ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktorija","family":"\u0136\u0113ni\u0146a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"39803_CR1","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1093\/brain\/awaa265","volume":"143","author":"F Eftimov","year":"2020","unstructured":"Eftimov, F., Lucke, I. M., Querol, L. A., Rajabally, Y. A. & Verhamme, C. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 143, 3214\u20133224 (2020).","journal-title":"Brain"},{"key":"39803_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40120-020-00184-6","volume":"9","author":"JA Allen","year":"2020","unstructured":"Allen, J. A. The misdiagnosis of CIDP: A review. Neurol. Ther. 9, 43\u201354 (2020).","journal-title":"Neurol. Ther."},{"key":"39803_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh, P. Y. K. et al. European academy of Neurology\/Peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task Force-Second revision. J. Peripher Nerv. Syst. 26, 242\u2013268 (2021).","journal-title":"J. Peripher Nerv. Syst."},{"key":"39803_CR4","doi-asserted-by":"publisher","unstructured":"Kotaich, F., Caillol, D. & Bomont, P. Neurofilaments in health and Charcot-Marie-Tooth disease. Front Cell. Dev. Biol 11, 1275155 (2023). https:\/\/doi.org\/10.3389\/fcell.2023.1275155","DOI":"10.3389\/fcell.2023.1275155"},{"key":"39803_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 90, 870\u2013881 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"39803_CR6","doi-asserted-by":"publisher","first-page":"e064184","DOI":"10.1002\/alz.064184","volume":"18","author":"D Figdore","year":"2022","unstructured":"Figdore, D. et al. Analytical validation of the Quanterix neurofilament light chain (NfL) advantage assay in plasma. Alzheimer\u2019s Dement. 18, e064184 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"39803_CR7","doi-asserted-by":"publisher","unstructured":"Hayashi, T. et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Behav. 11 (5), e02084  (2021). https:\/\/doi.org\/10.1002\/brb3.2084","DOI":"10.1002\/brb3.2084"},{"key":"39803_CR8","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/ene.15858","volume":"30","author":"S Setlere","year":"2023","unstructured":"Setlere, S. et al. Plasma neurofilament light chain level is not a biomarker of Charcot-Marie-Tooth disease progression: results of 3-year follow-up study. Eur. J. Neurol. 30, 2453\u20132460 (2023).","journal-title":"Eur. J. Neurol."},{"key":"39803_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"IN Van Schaik","year":"2010","unstructured":"Van Schaik, I. N. et al. European federation of neurological societies\/Peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society\u2013first revis. J. Peripher Nerv. Syst. 15, 295\u2013301 (2010).","journal-title":"J. Peripher Nerv. Syst."},{"key":"39803_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","volume":"16","author":"SM Murphy","year":"2011","unstructured":"Murphy, S. M. et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J. Peripher Nerv. Syst. 16, 191\u2013198 (2011).","journal-title":"J. Peripher Nerv. Syst."},{"key":"39803_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/ene.14689","volume":"28","author":"E Millere","year":"2021","unstructured":"Millere, E. et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur. J. Neurol. 28, 974\u2013981 (2021).","journal-title":"Eur. J. Neurol."},{"key":"39803_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jns.12608","volume":"29","author":"LS Kodal","year":"2024","unstructured":"Kodal, L. S., Witt, A. M., Pedersen, B. S., Aagaard, M. M. & Dysgaard, T. Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review. J. Peripher Nerv. Syst. 29, 17\u201327 (2024).","journal-title":"J. Peripher Nerv. Syst."},{"key":"39803_CR13","doi-asserted-by":"publisher","unstructured":"Oaklander, A. L. et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst. Rev 1, CD010369.pub2. (2017). https:\/\/doi.org\/10.1002\/14651858.CD010369.pub2.","DOI":"10.1002\/14651858.CD010369.pub2"},{"key":"39803_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00415-017-8474-3","volume":"264","author":"J Berciano","year":"2017","unstructured":"Berciano, J. et al. Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review. J. Neurol. 264, 1655\u20131677 (2017).","journal-title":"J. Neurol."},{"key":"39803_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","volume":"23","author":"S Mariotto","year":"2018","unstructured":"Mariotto, S. et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J. Peripher Nerv. Syst. 23, 174\u2013177 (2018).","journal-title":"J. Peripher Nerv. Syst."},{"key":"39803_CR16","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius, \u00c5. et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90, e518\u2013e524 (2018).","journal-title":"Neurology"},{"key":"39803_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.28054","volume":"69","author":"VEA Kleinveld","year":"2024","unstructured":"Kleinveld, V. E. A. et al. Multifocal motor neuropathy as a mimic of amyotrophic lateral sclerosis: serum neurofilament light chain as a reliable diagnostic biomarker. Muscle Nerve. 69, 422\u2013427 (2024).","journal-title":"Muscle Nerve"},{"key":"39803_CR18","doi-asserted-by":"publisher","unstructured":"Sanchez, J. D. et al. Temporal patterning of neurofilament light as a Blood-Based biomarker for stroke: A systematic review and Meta-Analysis. Front Neurol 13, 841898 (2022). https:\/\/doi.org\/10.3389\/fneur.2022.841898.","DOI":"10.3389\/fneur.2022.841898"},{"key":"39803_CR19","doi-asserted-by":"publisher","unstructured":"Ziemssen, T. et al. Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 ASCLEPIOS I and II trials. Front Immunol 13, 852563 (2022).https:\/\/doi.org\/10.3389\/fimmu.2022.852563.","DOI":"10.3389\/fimmu.2022.852563"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39803-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:57Z","timestamp":1781633877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39803"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39803-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9324"}}